We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+12.43%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$6.03B
AUM Growth
+$589M
Cap. Flow
+$81.4M
Cap. Flow %
1.35%
Top 10 Hldgs %
18.86%
Holding
1,529
New
146
Increased
642
Reduced
570
Closed
93

Sector Composition

Rank Sector Weight
1 Technology 19.32%
2 Financials 10.31%
3 Industrials 8.91%
4 Healthcare 8.6%
5 Consumer Discretionary 7.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SCHW
126
Charles Schwab
SCHW
$181B
$10.9M 0.18%
150,742
-13,339
-8% -$878K
CVS icon
127
CVS Health
CVS
$134B
$10.8M 0.18%
135,025
+6,137
+5% +$469K
MOAT icon
128
VanEck Morningstar Wide Moat ETF
MOAT
$11.8B
$10.6M 0.18%
118,341
+10,897
+10% +$935K
NVGS icon
129
Navigator Holdings
NVGS
$1.37B
$10.3M 0.17%
673,500
+102,224
+18% +$1.58M
IIIN icon
130
Insteel Industries
IIIN
$593M
$10.3M 0.17%
270,074
+27,553
+11% +$981K
IWD icon
131
iShares Russell 1000 Value ETF
IWD
$81.8B
$10.2M 0.17%
56,931
+5,884
+12% +$996K
VIG icon
132
Vanguard Dividend Appreciation ETF
VIG
$112B
$9.98M 0.17%
54,658
+1,148
+2% +$202K
KO icon
133
Coca-Cola
KO
$381B
$9.97M 0.17%
162,973
-10,580
-6% -$636K
XLF icon
134
State Street Financial Select Sector SPDR ETF
XLF
$56.8B
$9.91M 0.16%
235,335
-8,844
-4% -$349K
LIN icon
135
Linde
LIN
$235B
$9.9M 0.16%
21,325
-244
-1% -$106K
REGN icon
136
Regeneron Pharmaceuticals
REGN
$77.4B
$9.87M 0.16%
10,259
-1,869
-15% -$1.78M
GD icon
137
General Dynamics
GD
$103B
$9.81M 0.16%
34,710
-2,642
-7% -$707K
EHC icon
138
Encompass Health
EHC
$11B
$9.76M 0.16%
118,201
+6,280
+6% +$460K
IGSB icon
139
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$23B
$9.76M 0.16%
190,311
+8,030
+4% +$411K
APD icon
140
Air Products & Chemicals
APD
$66.8B
$9.76M 0.16%
40,269
+13,974
+53% +$3.42M
TJX icon
141
TJX Companies
TJX
$176B
$9.72M 0.16%
95,829
-3,274
-3% -$317K
XYL icon
142
Xylem
XYL
$27.3B
$9.52M 0.16%
73,646
-1,503
-2% -$182K
ADP icon
143
Automatic Data Processing
ADP
$105B
$9.47M 0.16%
37,917
+363
+1% +$88.7K
FCX icon
144
Freeport-McMoran
FCX
$91.2B
$9.42M 0.16%
200,244
+5,956
+3% +$240K
COP icon
145
ConocoPhillips
COP
$145B
$9.41M 0.16%
73,895
-43,541
-37% -$4.97M
ALLE icon
146
Allegion
ALLE
$13.4B
$9.24M 0.15%
68,603
+1,902
+3% +$244K
ZTS icon
147
Zoetis
ZTS
$31.9B
$9.22M 0.15%
54,460
-221
-0.4% -$41.4K
ADI icon
148
Analog Devices
ADI
$179B
$9.21M 0.15%
46,587
+2,417
+5% +$465K
NOBL icon
149
ProShares S&P 500 Dividend Aristocrats ETF
NOBL
$11.7B
$9.2M 0.15%
181,448
-33,666
-16% -$1.62M
UNP icon
150
Union Pacific
UNP
$172B
$9.17M 0.15%
37,293
-2,314
-6% -$569K

Similar funds

Oppenheimer & Co's Q1 2024 Portfolio in Review

As of Q1 2024, Oppenheimer & Co held 1,529 positions worth $6.03B, up 11% from $5.44B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Oppenheimer & Co's Q1 2024 filing shows 146 new, 642 increased, 570 reduced and 93 closed positions. Its largest new stake was State Street SPDR Portfolio Long Term Treasury ETF: 116,262 shares worth $3.25M. The largest sale was NVIDIA, an estimated $8.83M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 19% a quarter earlier, followed by Financials and Industrials.

  • Oppenheimer & Co's largest Q1 2024 buy was State Street SPDR Portfolio Long Term Treasury ETF: 116,262 shares worth $3.25M.
  • Oppenheimer & Co added most to State Street SPDR S&P 500 ETF Trust in Q1 2024, an estimated $7.26M increase.
  • Oppenheimer & Co's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $8.83M.
  • Oppenheimer & Co fully exited Pacer Developed Markets International Cash Cows 100 ETF in Q1 2024, selling an estimated $2.89M.
  • Oppenheimer & Co's ten largest holdings make up 19% of its $6.03B portfolio in Q1 2024.
  • Oppenheimer & Co opened 146 new positions and closed 93 in Q1 2024.
  • Oppenheimer & Co's portfolio value rose 11% quarter-over-quarter to $6.03B.

Based on Oppenheimer & Co's 13F filing for Q1 2024, filed 7 May 2024.